1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
657D946D56DCB2E1200258A160046F5FE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/insights/how-to-effectively-handle-investigator-initiated-and-collaborative-studies?opendocument
18
19opendocument
2044.192.94.177
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25Main






How to Effectively Handle Investigator-initiated and Collaborative Studies: Stay ahead of the curve

CHAPEL HILL, N.C., Feb. 10, 2023/PRNewswire/ -- Investigator-initiated studies (IISs) and collaborative research studies play a crucial role in helping biopharma organizations assess the cost-effectiveness of similar treatments and advance patient care. While organizations utilize IIS studies to expand the scale of their clinical programs, it is essential that they make sure to keep their costs in check.

Below are some of our key findings from the study:

  • A total of 88% of surveyed organizations have active IIS program in place, with nearly two thirds sponsoring studies for compounds in clinical phases
  • Global Medical Affairs is largely responsible for making the decision to support or reject IIS consideration of pre-approval compounds
  • Organizations conducting IISs cite post-marketing, expanded indications and gene therapies as key growth opportunity areas

“Benchmarking IIS Strategy: Maximizing Investigator-Initiated and Collaborative Study Capabilities” is a 38-page report that is designed to assist biopharma organizations benchmark their IIS capabilities, expand IIS usage, and improve overall approaches and impact.

Key topics in the report include:

  • IIS Program Management and Investment
  • Risk Mitigation Strategies
  • Collaborative Studies
  • Lessons Learned for IIS and Collaborative Research Success

The insights of this study were gained by engaging 27 leaders from 26 leading biopharma organizations.

To learn more about this report, download a complimentary report excerpt at https://www.best-in-class.com/rw185.htm.



ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis. The operational insights, findings and analysis form the basis for our Benchmarking Reports, databases and advisory services to support executives in commercial and R&D operations.